Ingo Bauerfeind
- Cancer Research top 0.5%
- Breast Cancer Treatment Studies 54
- Oncology top 1%
- HER2/EGFR in Cancer Research 26
- Cancer Treatment and Pharmacology 20
- Cancer Risks and Factors 7
-
- Breast Lesions and Carcinomas 18
- Genetics top 2%
- BRCA gene mutations in cancer 8
-
- Advanced Breast Cancer Therapies 14
-
- Breast Implant and Reconstruction 14
- Co-authors
- Michael UntchGϋnter von MinckwitzAnnette LebeauValentina NekljudovaKerstin HermelinkTanja FehmKarin MünzelBarbara Fleige
- Partner nations
- GermanySwitzerlandUnited States
In The Last Decade
Ingo Bauerfeind
99 papers receiving 4.3k citations
Hit Papers
Peers
Comparison fields: 5 of 125
- Cancer Research 2.2k
- Oncology 2.2k
- Pathology and Forensic Medicine 1.1k
- Genetics 454
- Pulmonary and Respiratory Medicine 1.0k
Countries citing papers authored by Ingo Bauerfeind
This map shows the geographic impact of Ingo Bauerfeind's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ingo Bauerfeind with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ingo Bauerfeind more than expected).
Fields of papers citing papers by Ingo Bauerfeind
This network shows the impact of papers produced by Ingo Bauerfeind. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ingo Bauerfeind. The network helps show where Ingo Bauerfeind may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Ingo Bauerfeind, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2020 | 8 | |
| 2 | 2016 | 9 | |
| 3 | 2016 | 43 | |
| 4 | 2016 | 49 | |
| 5 | 2015 | 53 | |
| 6 | 2013 | 51 | |
| 7 | Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort studybreakdown → | 2013 | 928 |
| 8 | 2012 | 15 | |
| 9 | 2011 | 1 | |
| 10 | 2010 | 9 | |
| 11 | 2009 | 36 | |
| 12 | 2008 | 20 | |
| 13 | 2008 | 70 | |
| 14 | The risk of non-sentinel metastases in primary breast cancer. | 2007 | 2 |
| 15 | 2006 | 5 | |
| 16 | 2005 | 1 | |
| 17 | 2005 | 4 | |
| 18 | 2004 | 4 | |
| 19 | 2003 | 454 | |
| 20 | 2000 | 20 |
About Ingo Bauerfeind
Ingo Bauerfeind is a scholar working on Cancer Research, Oncology and Pathology and Forensic Medicine, having authored 103 papers that have together received 4.4k indexed citations. Recurring topics across this work include Breast Cancer Treatment Studies (54 papers), HER2/EGFR in Cancer Research (26 papers), Cancer Treatment and Pharmacology (20 papers), Breast Lesions and Carcinomas (18 papers), Breast Implant and Reconstruction (14 papers), Advanced Breast Cancer Therapies (14 papers), BRCA gene mutations in cancer (8 papers) and Cancer Risks and Factors (7 papers). The work is most often cited by research in Cancer Research (2.2k citations), Oncology (2.2k citations) and Pathology and Forensic Medicine (1.1k citations). Ingo Bauerfeind has collaborated with scholars based in Germany, Switzerland and United States. Frequent co-authors include Michael Untch, Gϋnter von Minckwitz, Annette Lebeau, Valentina Nekljudova, Kerstin Hermelink, Tanja Fehm, Karin Münzel, Barbara Fleige, G Helms and Sabine Schmatloch. Their work appears in journals such as Journal of Clinical Oncology, Breast Care, Cancer Research, Annals of Oncology and JNCI Journal of the National Cancer Institute.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.